Royalty Pharma stock analysis
Royalty Pharma (RPD) Stock Price & Analysis
RPD Stock Chart & Stats
- Day’s Range
- EUR 62.66 - EUR 63.11
- 52-Week Range
- EUR 31.65 - EUR 63.80
- Previous Close
- EUR 62.32
- Volume
- N/A
- Average Volume (3M)
- 21
- Market Cap
- EUR 35.76B
- Enterprise Value
- EUR 43.51B
- Total Cash (Recent Filing)
- EUR 544.86M
- Total Debt (Recent Filing)
- EUR 8.59B
- Price to Earnings (P/E)
- 41.0
- Beta
- 0.32
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- 1.4
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.35%
Bulls Say, Bears Say
Bulls Say
Recurring Receipt Growth
Rising recurring royalty receipts and repeated guidance increases indicate durable demand across the underlying portfolio. This supports visibility into cash generation, strengthens funding capacity for new royalty acquisitions, and suggests growth is not dependent solely on occasional milestone payments.
High-margin Cash Generation
The royalty model converts a large share of receipts into portfolio cash flow because Royalty Pharma generally avoids direct drug development, manufacturing, and commercialization costs. High conversion can support acquisitions, debt service, and shareholder returns over the next several quarters.
Pipeline And Portfolio Diversification
A broad portfolio spanning multiple products and development programs can reduce reliance on any single medicine while creating avenues for future royalty growth. Successful approvals and pivotal trials expand the potential cash-flow base and reinforce the company’s sourcing advantage.
Bears Say
Meaningful Leverage
Debt provides acquisition capacity but creates a continuing claim on royalty cash flows through interest expense and principal obligations. Leverage can reduce flexibility if product receipts weaken or acquisition opportunities require additional funding, even with long debt duration and an undrawn revolver.
Maturing Product Headwinds
Declines from established products show that portfolio diversification does not eliminate erosion from aging or weakening assets. Continued pressure on major royalties could temper medium-term receipt growth and require successful replacement from newer products and development-stage investments.
Lower Contractual Receipts
Lower milestone and contractual receipts reduce a non-recurring contributor to total cash inflows and make results more dependent on underlying royalty collections. This may increase variability in reported revenue and limit the benefit of development events during the forecast period.
Royalty Pharma News
RPD FAQ
What was Royalty Pharma’s price range in the past 12 months?
What is Royalty Pharma’s market cap?
When is Royalty Pharma’s upcoming earnings report date?
How were Royalty Pharma’s earnings last quarter?
Is Royalty Pharma overvalued?
Does Royalty Pharma pay dividends?
What is Royalty Pharma’s EPS estimate?
How many shares outstanding does Royalty Pharma have?
What happened to Royalty Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Royalty Pharma?
What is the TipRanks Smart Score and how is it calculated?
Royalty Pharma Stock Smart Score
Company Description
Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Pablo Legorreta
- Employees
- 100
- Website
- www.royaltypharma.com
- Address
- 110 East 59th Street, New York, NY, 10022, US
Royalty Pharma (RPD) Earnings & Revenues
RPD Company Deck
RPD Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Royalty Receipts and Portfolio Receipts grew 9% in the quarter, year-to-date Royalty Receipts grew 12%, returns remained attractive, guidance was raised for the third consecutive quarter, and the company reported substantial clinical, regulatory, pipeline, capital allocation, and business-development momentum. The principal negatives were the pelacarsen Phase III failure and $150 million noncash impairment, product declines in Promacta and Imbruvica, and lower expected milestone receipts, but management emphasized protective deal structures and continued portfolio growth.
View all DE:RPD earnings summariesRPD Net sales Breakdown
- 93.34% Income from financial royalty assets
- 6.62% Other royalty income
- 0.04% Revenue from intangible royalty assets
RPD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 12 | 0 | 0 |











